Softwr

Healthcare · head to head

PathAI vs Techcyte

PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite
Techcyte logo

Techcyte

Healthcare

AI digital pathology across clinical, veterinary and environmental laboratory disciplines

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.; Techcyte regulatory status runs the opposite way to what most buyers assume: the products are CE marked and clinically deployed in Europe while several United States offerings including Fusion Parasitology are labelled research use only and not for diagnostic use, so an American laboratory must verify each module individually.
  • They diverge on capability: PathAI covers AISight image management, Techcyte covers Fusion Parasitology Suite.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which PathAI and Techcyte actually diverge.

Attributes where PathAI and Techcyte differ
AttributePathAITechcyte

Identical on both: starting price (On request), pricing model (quote), free tier (No), platforms (Web), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

Only in Techcyte

  • Fusion Parasitology Suite
  • Cervical cytology
  • Haematology
  • Urinalysis
  • Bacteriology and mycology
  • Vetcyte
  • Scanner agnostic ingestion
  • Remote review

What people use each for

The jobs each tool is most often brought in to do.

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Techcyte
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Techcyte
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Techcyte
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Techcyte

Techcyte

  • A clinical laboratory that cannot recruit technologists for high volume manual parasitology screening and needs AI pre screening with human releasenot PathAI
  • A veterinary reference laboratory processing large volumes of faecal and blood smears that wants Vetcyte to triage the normal casesnot PathAI
  • A European laboratory that can deploy the CE marked products clinically, which is where Techcyte regulatory position is strongestnot PathAI
  • An environmental testing laboratory needing consistent microscopy classification across analysts and sitesnot PathAI

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Techcyte

  • Regulatory status runs the opposite way to what most buyers assume: the products are CE marked and clinically deployed in Europe while several United States offerings including Fusion Parasitology are labelled research use only and not for diagnostic use, so an American laboratory must verify each module individually.
  • Slide scanning for parasitology, haematology and cytology needs multi plane imaging that a histology scanner may not produce, so a laboratory that already owns a scanner often has to buy new hardware, which becomes the biggest line in the project.
  • Each discipline is licensed separately, so a laboratory wanting parasitology, urinalysis and haematology assembles three modules and three validation studies rather than buying one platform.
  • AI pre screening does not remove the need for a qualified reviewer to release results, so the staffing saving is in review time per slide, not in headcount, and business cases that assume otherwise do not hold.
  • Techcyte covers a very wide set of disciplines, which means depth varies between them, and the maturity of a newer module is not the maturity of the parasitology or cytology products that made the company its name.

Pricing, plan by plan

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Techcyte

On request
  • Techcyte$undefined/year
    • Priced per slide or per annual specimen volume by discipline
    • Each discipline module licensed separately
    • Slide scanning hardware bought separately, not included

Which should you pick?

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Choose Techcyte if

  • You need fusion parasitology suite.
  • You also want cervical cytology.
Techcyte review

Questions people ask

Is PathAI or Techcyte better?
Neither clearly leads. PathAI starts at On request and Techcyte at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, PathAI or Techcyte?
PathAI starts at On request and Techcyte at On request.
Does PathAI or Techcyte run on more platforms?
Both run on Web, so platform support will not decide this one for you.
What is PathAI best used for?
PathAI is most often used for an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version, a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location, a pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readers, a laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewer. Of those, an academic medical centre going digital for primary diagnosis that needs the fda cleared aisight dx configuration rather than the research labelled version and a reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any location are not what Techcyte is typically brought in for.
What can PathAI do that Techcyte cannot?
PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management. Techcyte covers Fusion Parasitology Suite, Cervical cytology, Haematology, Urinalysis.

Answered from the vendors’ own pages

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Techcyte: Is Techcyte FDA cleared?

Not uniformly. Several United States offerings, including the Fusion Parasitology Suite, are labelled research use only and not for diagnostic use in the United States. Check the regulatory status of each specific module for your country before purchase.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Techcyte: Can we use it clinically in Europe?

Techcyte solutions are CE marked and clinically deployed across Europe, which is where its regulatory position is strongest. Confirm the current certificate for the specific module.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Techcyte: Does it eliminate the need for a technologist?

No. AI pre screens and prioritises, but a qualified reviewer still releases results. The saving is in review time per slide.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Techcyte: Do we need a specific scanner?

Techcyte works with several scanner vendors, but disciplines such as parasitology and haematology need multi plane imaging that many histology scanners cannot produce, so confirm hardware compatibility early.

Share

Related pages

More on PathAI

More on Techcyte

Keep looking

Other head to heads